Company news
Fortress Biotech, Inc. news in 2025
Fortress Biotech, Inc.'s news releases, calls and decks from 2025, newest first.
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission
December 15, 2025
Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
November 14, 2025
Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
November 13, 2025
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
November 6, 2025
Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025
November 4, 2025
Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics’ Global Phase 3 Trials of Dotinurad for the Treatment of Gout
October 21, 2025
Journey Medical Corporation to Participate in October 2025 Investor Conferences
October 7, 2025
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing
October 1, 2025
Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101
October 1, 2025
Journey Medical Corporation to Participate in September 2025 Investor Conferences
September 2, 2025
Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025
Journey Medical Corporation to Present at the Emerging Growth Conference
August 17, 2025
Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
August 14, 2025
Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11
August 6, 2025
Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025
August 4, 2025
Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™
July 13, 2025
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma
July 6, 2025
Journey Medical to Join Russell 2000® and Russell 3000® Indexes
June 23, 2025
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics
May 30, 2025
Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
May 15, 2025
Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates
May 12, 2025
Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference
May 7, 2025
Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer
March 31, 2025
Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights
March 31, 2025
Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea
March 23, 2025
Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025
March 18, 2025
Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform
March 17, 2025
Journey Medical Corporation to Participate in the 37th Annual ROTH Conference
March 11, 2025
Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement
March 4, 2025
Mustang Bio Announces Sale of Fixed Assets and Exit of Facility
February 26, 2025
Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT
January 26, 2025
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease
January 5, 2025
Calls in 2025
Decks in 2025
- Cellvation — Investor Presentation (May 2025)
Investor deck · 30 slides · May 2025
- Helocyte — Investor Presentation (March 2025)
Investor deck · 38 slides · March 2025